Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents

Ophthalmology

Volumn 118, Issue 10, 2011, Pages 2028-2034

  Shah, Chirag P ^a,b   Garg, Sunir J ^b   Vander, James F ^b   Brown, Gary C ^b   Kaiser, Richard S ^b   Haller, Julia A ^b  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; RANIBIZUMAB;

ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONJUNCTIVA DISPLACEMENT; ENDOPHTHALMITIS; HUMAN; HYPOPYON; PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCUS; VISION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; CASE-CONTROL STUDIES; CEFTAZIDIME; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TOBRAMYCIN; TREATMENT OUTCOME; VANCOMYCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 80053608306     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.02.034     Document Type: Article

References (35)

1. D.M. Brown, P.A. Campochiaro, R.P. Singh CRUISE Investigators Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1124 1133
2. P.A. Campochiaro, J.S. Heier, L. Feiner BRAVO Investigators Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1102 1112
3. M.E. Gheith, G.A. Siam, and D.S. de Barros Role of intravitreal bevacizumab in neovascular glaucoma J Ocul Pharmacol Ther 23 2007 487 491 (Pubitemid 350202480)
4. M.J. Elman, L.P. Aiello, R.W. Beck Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
5. N.M. Pharmakakis, I.K. Petropoulos, and C.D. Georgakopoulos Apoptotic mechanisms within the retina in Staphylococcus epidermidis experimental endophthalmitis Graefes Arch Clin Exp Ophthalmol 247 2009 667 674
6. K.S. Klein, M.K. Walsh, and T.S. Hassan Endophthalmitis after anti-VEGF injections [letter] Ophthalmology 116 2009 1225
7. T. Diago, C.A. McCannel, and S.J. Bakri Infectious endophthalmitis after intravitreal injection of antiangiogenic agents Retina 29 2009 601 605
8. S. Pilli, A. Kotsolis, and R.F. Spaide Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting Am J Ophthalmol 145 2008 879 882
9. T. Ness, N. Feltgen, and H. Agostini Toxic vitritis outbreak after intravitreal injection Retina 30 2010 332 338
10. M. Georgopoulos, K. Polak, and F. Prager Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin) Br J Ophthalmol 93 2009 457 462
11. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431 (Pubitemid 44511557)
12. D.M. Brown, M. Michels, P.K. Kaiser ANCHOR Study Group Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study Ophthalmology 116 2009 57 65
13. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444 (Pubitemid 44511558)
14. D.R. Fintak, G.K. Shah, and K.J. Blinder Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab Retina 28 2008 1395 1399
15. D.S. Fong, P. Custis, J. Howes, and J.W. Hsu Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study Ophthalmology 117 2010 298 302
16. K. Yamashiro, A. Tsujikawa, and K. Miyamoto Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch Retina 30 2010 485 490
17. S.S. Wickremasinghe, K. Michalova, and J. Gilhotra Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration Ophthalmology 115 2008 1911 1915
18. D. Mezad-Koursh, M. Goldstein, and G. Heilwail Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor Retina 30 2010 1051 1057
19. J.O. Mason III, M.F. White, and R.M. Feist Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection Retina 28 2008 564 567 (Pubitemid 351589565)
20. M.G. Speaker, and J.A. Menikoff Prophylaxis of endophthalmitis with topical povidone-iodine Ophthalmology 98 1991 1769 1775
21. J.M. Moss, S.R. Sanislo, and C.N. Ta A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections Ophthalmology 116 2009 1498 1501
22. J.H. Boden, M.L. Myers, and T. Lee Effect of lidocaine gel on povidone-iodine antisepsis and microbial survival J Cataract Refract Surg 34 2008 1773 1775
23. S. Awotesu, and T. Eke Preoperative lidocaine gel [letter] Ophthalmology 117 2010 1049 author reply 1049
24. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials Ophthalmology 113 2006 992 1001
25. C.N. Ta Minimizing the risk of endophthalmitis following intravitreous injections Retina 24 2004 699 705 (Pubitemid 39391759)
26. I.U. Scott, and H.W. Flynn Jr Reducing the risk of endophthalmitis following intravitreal injections Retina 27 2007 10 12 (Pubitemid 46095824)
27. A.R. Bhavsar, J.M. Googe Jr, C.R. Stockdale Diabetic Retinopathy Clinical Research Network Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the Diabetic Retinopathy Clinical Research Network laser-ranibizumab-triamcinolone clinical trials Arch Ophthalmol 127 2009 1581 1583
28. L.P. Aiello, A.J. Brucker, and S. Chang Evolving guidelines for intravitreous injections Retina 24 suppl 2004 S3 S19
29. E.J. Higginbotham, R.K. Stevens, and D.C. Musch Bleb-related endophthalmitis after trabeculectomy with mitomycin C Ophthalmology 103 1996 650 656 (Pubitemid 26114237)
30. I. Mac, and J.B. Soltau Glaucoma-filtering bleb infections Curr Opin Ophthalmol 14 2003 91 94 (Pubitemid 36584228)
31. J.H. Dunnington, and D. Locatcher-Khorazo Value of cultures before operation for cataract Arch Ophthal 34 1945 215 219
32. S.J. Garg, and F.M. Recchia Re: Evolving guidelines for intravitreous injections [letter] Retina 25 2005 949 950 author reply 950
33. Endophthalmitis Vitrectomy Study Group Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis Arch Ophthalmol 113 1995 1479 1496
34. M. Barza, P.R. Pavan, B.H. Doft Endophthalmitis Vitrectomy Study Group Evaluation of microbiological diagnostic techniques in postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study Arch Ophthalmol 115 1997 1142 1150 (Pubitemid 27387950)
35. S.J. Bakri, T.A. Larson, and A.O. Edwards Intraocular inflammation following intravitreal injection of bevacizumab Graefes Arch Clin Exp Ophthalmol 246 2008 779 781